Results 71 to 80 of about 4,586,589 (282)

Anti-amyloid therapies: are they effective and safe?

European Psychiatry
Abstract After numerous unsuccessful attempts to create a therapy that could alter the course of Alzheimer’s disease, first monoclonal antibodies targeting amyloid-β in the brain have finally shown consistent evidence of clinical effectiveness. These therapies not only slow the progression of the disease, but also show positive results in secondary ...
openaire   +2 more sources

An Anti‐Amyloidogenic Approach to Specifically Block Memory Consolidation in Mice for Therapeutic Intervention

Advanced Science, EarlyView.
Functional amyloid conversion of the translation regulator CPEB3 is essential for long‐term memory persistence. This study demonstrates that targeting this molecular switch with the anti‐amyloidogenic peptide QBP1 selectively blocks CPEB3 fibrillation without disrupting phase separation.
Paula López‐García, Kerry R. McGreevy, Maria Eugenia Vaquero, Juan M. Suarez‐Rivero, Antonio Moreno‐Rodríguez, Antonio J. Pérez‐Pulido, Daniel Ramírez de Mingo, Anna Pallé, Helena Akiko Popiel, Andrea Santi, Mario D. Cordero, José Luis Trejo, Yoshitaka Nagai, Mariano Carrión‐Vázquez   +13 more
wiley   +1 more source

Uptake and safety profile of anti-amyloid immunotherapies in routine clinical practice

Journal of Alzheimer's Disease Reports
Background Anti-amyloid immunotherapies are approved by the United States Food and Drug Administration for the treatment of Alzheimer's disease; however, the adoption and safety profile of these medications in routine clinical practice have not been ...
Jay B. Lusk, Kate Vinita Fitch, Kim G. Johnson, Andy Liu, Jennifer L. Lund, Laine E. Thomas, Ryan McDevitt, Anqi Zhao, Heather E. Whitson, Richard O'Brien, Shannon Aymes, Bradley G. Hammill, Brian Mac Grory, Fan Li, Emily C. O'Brien   +14 more
doaj   +1 more source

Microglial Deubiquitinase OTUD7B Stabilizes STAT3 to Promote Neuroinflammation and Cognitive Decline in Alzheimer's Disease

Advanced Science, EarlyView.
. ABSTRACT Neuroinflammation driven by microglial activation is a defining feature of Alzheimer's disease (AD), yet the molecular mechanisms sustaining this proinflammatory state remain unclear. Here, we identify the deubiquitinase OTUD7B as a critical regulator of microglial activation and AD pathology.
Luyao Li, Hao Tang, Qin Yu, Yuyang Zhang, Binglu Shi, Ying Kong, Leiyu Xu, Jingjing Shao, Chenghong Hu, Lingyu She, Zhe Wang, Haiyi Chen, Aleksandr V. Samorodov, Gang Cao, Xia Zhao, Yi Wang   +15 more
wiley   +1 more source

Brain metabolic imaging-based model identifies cognitive stability in prodromal Alzheimer’s disease

Scientific Reports
The recent approval of anti-amyloid pharmaceuticals for the treatment of Alzheimer’s disease (AD) has created a pressing need for the ability to accurately identify optimal candidates for anti-amyloid therapy, specifically those with evidence for ...
Jarrad Perron, Carly Scramstad, Ji Hyun Ko   +2 more
doaj   +1 more source

Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review

Neuroscience
Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting millions worldwide, and with advancements in the medical field, Anti-amyloid monoclonal antibodies (AA mAbs) targeting amyloid-β have emerged as potential disease-modifying agents altering AD pathology.
Shahd Abubaker Elamin, Aous N. Al Shibli, Abdullah Shaito, Mazyona J.M.B. Al-Maadhadi, Monica Zolezzi, Shona Pedersen   +5 more
openaire   +2 more sources

Synthese und Charakterisierung von dualen Gamma-Sekretase - PPARgamma-Modulatoren als potentielle Wirkstoffe zur Therapie von Morbus Alzheimer [PDF]

, 2011
Morbus Alzheimer ist eine neurodegenerative Erkrankung, die weltweit die häufigste Ursache einer Demenz darstellt. Da neben genetischer Prädisposition vor allem ein hohes Lebensalter einen Hauptrisikofaktor für die Erkrankung darstellt, erwartet man für ...
Hieke, Martina
core  

Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing

Advanced Science, EarlyView.
Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale, Marie Celine Lefevre, Alessio Carmignani, Maria Cristina Ceccarelli, Matteo Battaglini, Attilio Marino, Gianni Ciofani   +6 more
wiley   +1 more source

Natural history and outcome in systemic AA amyloidosis [PDF]

, 2007
BACKGROUND:Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders.
Goodman, HJB, Lachmann, HJ, Gillmore, JD, Hawkins, PN, Gilbertson, JA, Gallimore, JR, Sabin, CA   +6 more
core  

Molecular Editing Reveals a Bilobalide Chemotype that Attenuates Prolyl Endopeptidase (PREP)‐Linked Neuroinflammation

Advanced Science, EarlyView.
Molecular editing of bilobalide uncovers BB56, a PREP‐engaging chemotype with enhanced anti‐inflammatory activity in microglia. Integrated CETSA‐MS, SAR, and pathway analyses link BB56 to attenuation of p38 MAPK/NF‐κB and NLRP3‐associated inflammatory signaling, highlighting bilobalide editing as a strategy for developing neuroinflammation‐modulating ...
Chanin Sillapachaiyaporn, Wenjing Wang, Yao Qin, Lili Yan, Stephan Scheeff, Xu He, Qiong Wu, Yue Lin, Jinsai Shang, Xin Ye, Jing Liu, Kailei Sun, Chun Wai Yeung, Junzhe Huang, Zhenghui Chen, Xiaodong Liu, Yiqun Geng, Shannon Wing Ngor Au, Bonaventure Y. Ip, Ho Ko, Billy Wai‐Lung Ng   +20 more
wiley   +1 more source